Blood Reviews
Volume 19, Issue 2 , Pages 99-110 , March 2005

Three decades of innovation in the management of sickle cell disease: the road to understanding the sickle cell disease clinical phenotype

References 

  1. Gaston MH, Rosse WF and the Cooperative Group. The cooperative study of sickle cell disease: review of study design and objectives. Am J Pediatr Hematol/Oncol 1982;4:197–201
  2. Gaston M, Smith J, Gallagher D, Flournoy-Gill Z, West S, Bellevue R, et al. and the CSSCD Study Group. Recruitment in the cooperative study of sickle cell disease (CSSCD). Contr Clin Trials 1987;8:131S–40S
  3. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, et al. and the Prophylactic Penicillin Study Group. Prophylaxis with oral penicillin in children with sickle cell anemia. New Engl J Med 1986;314:1593–99
  4. Gaston M, Verter J. Sickle cell anaemia trial. Stat. Med. 1990;9:45–51
  5. Platt O, Thorington BD, Brambilla DJ, Milner PF, Rosse W, Vichinsky E, et al.  Pain in sickle cell disease: rates and risk factors. New Engl. J. Med. 1991;325:11–16
  6. Farber MD, Koshy M, Kinney TR and the Cooperative Group. Cooperative study of sickle cell disease: demographic and socioeconomic characteristics of patients and families with sickle cell disease. J Chron Dis 1985;38:495–505
  7. West MS, Wethers D, Smith J, Steinberg M. and the Cooperative Study of Sickle Cell Disease. Laboratory profile of sickle cell disease: a cross-sectional analysis. J Clin Epidemiol 1992;45:893–909
  8. Brown AK, Sleeper LA, Miller S, Pegelow C, Gill F, Waclawiw M. Reference values and hematologic changes from birth to five years in patients with sickle cell disease. Arch. Pediatr. Adolescent Med. 1994;148:1156–1162
  9. Pearson HA, Gallagher MS, Chilcote R, Sullivan E, Wilmas J, Espeland M, et al. and the Cooperative Group. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics 1985;76:392–97
  10. Koshy M, Entsuah R, Koranda A, Kraus AP, Johnson R, Bellevue R, et al.  Leg ulcers in patients with sickle cell disease. Blood. 1989;74:1403–1408
  11. Milner PF, Kraus AP, Sebes JI, Sleeper LA, Dukes KA, Embury SH, et al.  Sickle cell disease as a cause of osteonecrosis of the femoral head. New Engl. J. Med. 1991;325:1476–1481
  12. Milner PF, Kraus AP, Sebes JI, Sleeper LA, Dukes KA, Embury SH, et al.  Osteonecrosis of the humeral head in sickle cell disease. Orthop. Rel. Res. 1993;289:136–143
  13. Wang WC, Grover R, Gallagher D, Espeland M, Fandal A. Developmental screening in young children with sickle cell disease: results of a cooperative study. Am. J. Pediatr. Hematol. Oncol. 1993;15:87–91
  14. Armstrong FD, Thompson RJ, Wang W, Zimmerman R, Pegelow CH, Miller S, et al.  Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease. Pediatrics. 1996;97:864–870
  15. Moser FG, Miller ST, Bello JA, Pegelow CH, Zimmerman RA, Wang WC, et al.  The spectrum of brain MR abnormalities in sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. Am. J. Neuroradiol. 1996;17:965–972
  16. Ohene-Frempong F, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, et al.  Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288–294
  17. Kinney TR, Sleeper LA, Wang WC, Zimmerman RA, Pegelow CH, Ohene-Frempong K, et al.  Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. Pediatrics. 1999;103:640–645
  18. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, et al.  The acute chest syndrome in sickle cell disease: incidence and risk factors. Blood. 1994;84:643–649
  19. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Blood. 1997;89:1787–1792
  20. Covitz W, Espeland M, Gallagher D, Hellenbrand W, Leff S, Talner N. The heart in sickle cell anemia: the cooperative study of sickle cell disease (CSSCD). Chest. 1995;108:1214–1219
  21. Rosse WF, Gallagher D, Kinney TR, Castro O, Dosik H, Moohr J, et al. and the CSSCD. Transfusion and alloimmunization in sickle cell disease. Blood 1990;76:1431–7
  22. Platt OS, Rosenstock W, Espeland MA. Influence of sickle hemoglobinopathies on growth and development. New Engl. J. Med. 1984;311:7–12
  23. Espeland MA, Gallagher D, Tell GS, Davison LL, Platt OS. Reliability of Tanner stage assessments in a multi-center study. Am. J. Hum. Biol. 1990;2:503–510
  24. Zarkowsky HS, Gallagher D, Gill FM, Wang W, Falletta JM, Lande WM, et al. and the Cooperative Group. Bacteremia in sickle hemoglobinopathies. J Pediatr 1986;109:579–85
  25. Gill F, Gallagher D, et al.  Newborn experience in the cooperative study of sickle cell disease. Pediatr. Suppl. 1989;83:827–829
  26. Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, et al.  Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood. 1995;86:776–783
  27. Brown AK, Sleeper LA, Pegelow CH, Miller ST, Gill FM, Waclawiw MA. The influence of infant and maternal sickle cell disease on birth outcome and neonatal course. Arch. Pediatr. Adolescent Med. 1994;148:1156–1162
  28. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W and the CSSCD. Mortality in children and adolescents with sickle cell disease. Pediatrics 1989;84:500–8
  29. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, et al.  Prediction of adverse outcomes in children with sickle cell disease. New Engl. J. Med. 2000;342:83–89
  30. Koshy M, Weiner SJ, Miller ST, Sleeper LA, Vichinsky E, Brown AK, et al.  Surgery and anesthesia in sickle cell disease. Blood. 1995;86:3676–3684
  31. Smith JA, Espeland M, Bellevue R, Bonds D, Brown AK, Koshy M. Pregnancy in sickle cell disease: experience of the cooperative study of sickle cell disease. Obstet. Gynecol. 1996;87:199–204
  32. Pegelow CH, Colangelo L, Steinberg M, Wright EC, Smith J, Phillips G, et al.  Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am. J. Med. 1997;102:171–177
  33. Platt O, Brambilla DJ, Rosse W, Milner PF, Castro O, Steinberg MH, et al.  Mortality in sickle cell disease: life expectancy and risk factors for early death. New Engl. J. Med. 1994;330:1639–1644
  34. Steinberg MH, Rosenstock W, Coleman MB, Adams JG, Platica O, Cedeno M, et al. and the Cooperative Group. Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of sickle cell anemia. Blood 1984;63:1353–60
  35. Embury SH, Gholson MA, Gillette P, Rieder RF. and the Cooperative Group. The leftward deletion [α-THAL-2] á-Thal-2 haplotype in a black subject with hemoglobin SS. Blood 1985;65:769–71
  36. Espeland M. Estimation of growth curves from longitudinal data collected at irregular time intervals. Comput. Biomed. Res. 1986;19:575–587
  37. Steinberg MH, West MS, Gallagher D, Mentzer W and the CSSCD. Effects of glucose-6-phosphate dehydrogenase deficiency upon sickle cell disease. Blood 1988;71:748–52
  38. Espeland MA, Platt OS, Gallagher D. Joint estimation of incidence and diagnostic error rates from irregular longitudinal data. J. Am. Stat. Assoc. 1989;84:972–979
  39. Espeland M, Rushing JT, DeVault A. Estimating incidence and diagnostic error rates for bivariate progressive processes. Biometrics. 1993;49:1010–1021
  40. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al.  Causes and outcomes of the acute chest syndrome in sickle cell disease. New Engl. J. Med. 2000;342:1855–1865
  41. Falletta JM, Woods GM, Verter JI, Buchanan GR, Pegelow CH, Iyer RV, et al.  Discontinuing penicillin prophylaxis in children with sickle cell anemia. J. Pediatr. 1995;127:685–690
  42. Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, et al.  Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 1992;79:2555–2565
  43. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New Engl. J. Med. 1995;332:1317–1322
  44. Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, et al.  Hydroxyurea and sickle cell anemia: clinical utility of a myelosuppressive “switching” agent. Medicine. 1996;75:300–325
  45. Lu Z, Steinberg MH. Fetal hemoglobin in sickle cell anemia: relation to regulatory sequences cis to the Beta-globin gene. Blood. 1996;87:1604–1611
  46. Hackney AC, Hezier W, Gulledge TP, Jones S, Strayhorn D, Busby M, et al.  Effects of hydroxyurea administration on the body-weight, body composition, and exercise performance of patients with sickle cell anaemia. Clin. Sci. 1997;92:481–486
  47. Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK and the Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. Am J Hematol 2000;64:26–31
  48. Vichinsky EP, Haberkern CM, Neumayr LD, Earles AN, Black D, Koshy M, et al.  A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. New Engl. J. Med. 1995;333:206–213
  49. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al.  Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New Engl. J. Med. 1998;339:5–11
  50. Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, et al.  Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS Study, a phase I/II trial. Blood. 1999;94:1550–1554
  51. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al.  Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia; risks and benefits up to9 years of treatment. J. Am. Med. Assoc. 2003;289:1645–1651

PII: S0268-960X(04)00020-7

doi: 10.1016/j.blre.2004.04.002

Blood Reviews
Volume 19, Issue 2 , Pages 99-110 , March 2005

Article Tools